Online Table 1. Clinical Outcomes During Follow-up in ST-elevation MI Patients Following Primary Percutaneous Coronary Intervention

(n=5492)

OutcomesBP-DES group

(n=1166)

Second-generation

DP-DES group (n=4326)

Adjusted HR

(95% CI)p

All-cause death 74 (6.3%) 349 (8.1%) 0.806 (0.633-0.972) 0.039

Cardiac death 50 (4.3%) 264 (6.1%) 0.784 (0.588-0.946) 0.048

Non-cardiac death 24 (2.1%) 85 (2.0%) 1.035 (0.658-1.629) 0.839

Recurrent MI 16 (1.4%) 101 (2.3%) 0.587 (0.346-0.995) 0.043

Any revascularization 61 (5.2%) 266 (6.1%) 0.894 (0.549-1.856) 0.218

Re-PCI 57 (4.9%) 256 (5.9%) 0.822 (0.617-1.096) 0.178

CABG 4 (0.3%) 10 (0.2%) 1.513 (0.474-4.829) 0.501

Stroke 10 (0.9%) 69 (1.6%) 0.535 (0.276-0.838) 0.036

HF readmission 20 (1.7%) 128 (3.0%) 0.572 (0.357-0.917) 0.020

Definite/probable ST 5 (0.4%) 27 (0.6%) 0.682 (0.263-1.772) 0.437

Late ST 3 (0.3%) 10 (0.2%) 0.797 (0.552-1.876) 0.215

Very late ST 1 (0.1%) 8 (0.2%) 0.336 (0.043-2.606) 0.297

Late/very late ST 4 (0.3%) 18 (0.4%) 0.774 (0.263-2.276) 0.642

MACEs* 151 (13.0%) 716 (16.6%) 0.827 (0.563-0.915) 0.017

NACEs† 186 (15.9%) 940 (21.7%) 0.766 (0.647-0.907) 0.002

Values are shown as n (%). BP-DES, biodegradable polymer drug-eluting stent; CABG, coronary artery bypass graft; CI, confidence interval; DP-DES, durable

polymer drug-eluting stent; HF, heart failure; HR, hazard ratios; MACEs, major adverse cardiac events; MI, myocardial infarction; NACEs, net adverse clinical

events; Re-PCI, repeat percutaneous coronary intervention; ST, stent thrombosis.

*MACEs included all-cause death, recurrent MI, or any revascularization with Re-PCI or CABG

†NACEs included all-cause death, recurrent MI, any revascularization with Re-PCI or CABG, stroke, HF readmission, or definite/probable ST.

Online Figure Legend

Online Figure 1. Independent predictors of MACE

Entire (A) and Propensity score-matched (B) cohorts.

BP-DES, biodegradable polymer drug-eluting stent; CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiac events.

Online Figure 2. Subgroup analysis of major adverse cardiac events.

Standard Cox regression (A), Propensity score–matched (B), and Propensity score-adjusted (C) analyses.

BP-DES, biodegradable polymer drug-eluting stent; CI, confidence interval; DP-DES, durable polymer drug-eluting stent; HR, hazard ratio;

LVEF, left ventricular ejection fraction; STEMI, ST-elevation myocardial infarction.

Online Table 2. Medications Received at Discharge, 1-year Follow-up, and 2-year Follow-up

BP-DES group

(n=2261)

Second-generation

DP-DES group (n=8182)p

Discharge medications

Aspirin 2256 (99.8%) 8166 (99.8%) 0.792

Clopidogrel 1342 (59.4%) 5220 (63.8%) 0.727

Ticagrelor 533 (23.6%) 1963 (24.0%) 0.302

Prasugrel 381 (16.8%) 982 (12.0%) <0.001

DAPT 2256 (99.8%) 8166 (99.8%) 0.792

Cilostazol 247 (10.9%) 904 (11.0%) 0.907

Beta-blocker 1894 (83.8%) 6942 (84.8%) 0.211

Calcium channel blocker 110 (4.9%) 469 (5.7%) 0.121

ACEi or ARB 1817 (80.4%) 6606 (80.7%) 0.201

Statin 2116 (93.6%) 7588 (92.7%) 0.180

1-year follow-up

Aspirin 2024 (89.5%) 7446 (91.0%) 0.083

Clopidogrel 1311 (58.0%) 4852 (59.3%) 0.235

Ticagrelor 115 (5.1%) 475 (5.8%) 0.225

Prasugrel 163 (7.2%) 401 (4.9%) <0.001

DAPT 1589 (70.3%) 5727 (70.0%) 0.164

Cilostazol 45 (2.0%) 278 (3.4%) 0.001

Beta-blocker 1773 (78.4%) 6529 (79.8%) 0.174

Calcium channel blocker 289 (12.8%) 1129 (13.8%) 0.243

ACEi or ARB 1698 (75.1%) 6096 (74.5%) 0.566

Statin 2116 (93.6%) 7658 (93.6%) 0.959

2-year follow-up

Aspirin 1572 (69.5%) 5662 (69.2%) 0.661

Clopidogrel 1183 (52.3%) 4279 (52.3%) 0.651

Ticagrelor 32 (1.4%) 90 (1.1%) 0.004

Prasugrel 81 (3.6%) 196 (2.4%) 0.119

DAPT 949 (42.0%) 3409 (41.7%) 0.920

Cilostazol 70 (3.1%) 221 (2.7%) 0.383

Beta-blocker 1712 (75.7%) 6227 (76.1%) 0.695

Calcium channel blocker 350 (15.5%) 1374 (16.8%) 0.198

ACEi or ARB 1655 (73.2%) 5883 (71.9%) 0.261

Statin 2116 (93.6%) 7617 (93.1%) 0.443

Values are presented as n (%).

ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blockers; BP-DES, biodegradable polymer drug-eluting stent;

DAPT, Dual antiplatelet therapy; DP-DES, durable polymer drug-eluting stent.

Online Table 3. Clinical Outcomes According to Stent Type During Follow-up

BP-BES

(n=1951)

BP-SES

(n=310)

DP-EES

(n=5623)

DP-ZES

(n=2559)

Adjusted HR

(95% CI)

BP-BES

vs. DP-EES

Adjusted HR

(95% CI)

BP-BES

vs. DP-ZES

Adjusted HR

(95% CI)

BP-SES

vs. DP-EES

Adjusted HR

(95% CI)

BP-SES

vs. DP-ZES

All-cause death 115 (5.9%) 16 (5.2%) 438 (7.8%) 176 (6.9%) 0.731 (0.599-0.892) 0.860 (0.683-0.983) 0.725 (0.440-0.979) 0.824 (0.507-0.938)

Cardiac death 69 (3.5%) 12 (3.9%) 296 (5.3%) 120 (4.7%) 0.589 (0.456-0.761) 0.725 (0.540-0.972) 0.655 (0.368-0.967) 0.805 (0.445-0.945)

Non-cardiac death 46 (2.4%) 4 (1.3%) 142 (2.5%) 56 (2.2%) 0.973 0.786-1.490) 0.898 (0.788-1.671) 0.832 (0.367-1.886) 0.864 (0.372-2.006)

Recurrent MI 32 (1.6%) 3 (1.0%) 148 (2.6%) 54 (2.1%) 0.647 (0.442-0.946) 0.766 (0.495-1.184) 0.518 (0.192-0.901) 0.616 (0.223-0.937)

Any revascularization 90 (4.6%) 17 (5.5%) 281 (5.0%) 122 (4.8%) 0.874 (0.672-1.554) 0.745 (0.437-1.478) 0.984 (0.673-3.786) 0.915 (0.468-5.353)

Re-PCI 84 (4.3%) 15 (4.8%) 263 (4.7%) 112 (4.4%) 0.904 (0.722-1.131) 0.847 (0.658-1.092) 0.964 (0.662-1.712) 1.000 (0.612-1.631)

CABG 6 (0.3%) 2 (0.6%) 18 (0.3%) 10 (0.4%) 0.649 (0.793-2.151) 0.671 (0.225-2.003) 0.321 (0.094-1.095) 0.741 (0.457-5.468)

Stroke 23 (1.2%) 4 (1.3%) 80 (1.4%) 45 (1.8%) 0.779 (0.490-1.238) 0.580 (0.353-0.953) 0.906 (0.332-2.473) 0.654 (0.236-1.813)

HF readmission 32 (1.6%) 5 (1.6%) 170 (3.0%) 68 (2.7%) 0.557 (0.387-0.802) 0.638 (0.423-0.961) 0.525 (0.216-1.078) 0.603 (0.243-1.196)

Definite/probable ST 10 (0.5%) 2 (0.6%) 29 (0.5%) 16 (0.6%) 0.851 (0.536-2.344) 0.793 (0.503-2.902) 0.804 (0.355-6.364) 0.894 (0.351-4.306)

MACEs* 237 (12.1%) 36 (11.6%) 867 (15.4%) 352 (13.8%) 0.814 (0.593-0.921) 0.825 (0.629-0.942) 0.836 (0.575-0.937) 0.826 (0.614-0.925)

NACEs† 302 (15.5%) 47 (15.2%) 1144 (20.3%) 480 (18.8%) 0.757 (0.662-0.866) 0.803 (0.689-0.936) 0.810 (0.632-0.942) 0.797 (0.661-0.974)

Values are shown as n (%). BP-BES, biodegradable polymer biolimus-eluting stent; BP-SES, biodegradable polymer sirolimus-eluting stent; CABG, coronary

artery bypass graft; CI, confidence interval; DP-EES, durable polymer everolimus-eluting stent; DP-ZES, durable polymer zotarolimus-eluting stent; HF, heart

failure; HR, hazard ratios; MACEs, major adverse cardiac events; MI, myocardial infarction; NACEs, net adverse clinical events; Re-PCI, repeat percutaneous

coronary intervention; ST, stent thrombosis.

*MACEs included all-cause death, recurrent MI, or any revascularization with Re-PCI or CABG

†NACEs included all-cause death, recurrent MI, any revascularization with Re-PCI or CABG, stroke, HF readmission, or definite/probable ST.

Online Table 4. Clinical Outcomes According to Stent Strut Thickness

Outcomes 60 µm vs. 81

µm

60 µm vs. 91

µm

60 µm vs. 120

µm

81 µm vs. 91

µm

81 µm vs. 120

µm

91 µm vs. 120

µm

All-cause death 0.758 (0.547-

0.962)

0.837 (0.672-

0.981)

0.815 (0.653-

0.938)

0.917 (0.624-

1.476)

0.935 (0.619-

1.524)

0.816 (0.695-

1.314)

Cardiac death 0.694 (0.426-

0.971)

0.722 (0.458-

0.965)

0.738 (0.507-

0.973)

0.924 (0.598-

1.384)

0.828 (0.563-

1.612)

0.854 (0.574-

1.247)

Non-cardiac

death

0.853 (0.417-

1.614)

0.848 (0.425-

1.947)

0.914 (0.493-

1.874)

0.903 (0.716-

1.418)

0.912 (0.704-

1.379)

0.823 (0.682-

1.544)

Recurrent MI 0.567 (0.324-

0.946)

0.551 (0.341-

0.972)

0.683 (0.418-

0.926)

0.846 (0.579-

1.752)

0.754 (0.522-

1.967)

0.647 (0.454-

1.824)

Any

revascularization

0.991 (0.734-

3.165)

0.891 (0.617-

3.815)

0.934 (0.684-

3.649)

0.893 (0.517-

1.479)

0.818 (0.598-

1.692)

0.852 (0.493-

1.527)

Re-PCI 0.979 (0.716-

1.541)

0.984 (0.681-

1.357)

0.968 (0.615-

1.348)

0.912 (0.545-

1.392)

0.885 (0.612-

1.384)

0.877 (0.518-

1.409)

CABG 0.632 (0.345-

1.157)

0.628 (0.562-

4.176)

0.674 (0.394-

2.457)

0.704 (0.457-

2.483)

0.697 (0.414-

2.521)

0.716 (0.352-

2.348)

Stroke 0.964 (0.418-

2.239)

0.716 (0.386-

1.531)

0.791 (0.427-

1.942)

0.907 (0.586-

1.745)

0.915 (0.528-

1.825)

0.892 (0.437-

1.573)

HF readmission 0.654 (0.368-

1.182)

0.724 (0.358-

1.364)

0.633 (0.419-

1.586)

0.791 (0.478-

1.684)

0.784 (0.429-

1.236)

0.793 (0.548-

1.614)

Definite/probable

ST

0.825 (0.455-

4.824)

0.843 (0.501-

3.672)

0.847 (0.525-

5.637)

0.876 (0.549-

1.962)

0.923 (0.694-

2.548)

0.849 (0.529-

2.245)

MACEs* 0.868 (0.591- 0.798 (0.685- 0.881 (0.612- 0.957 (0.607- 0.907 (0.643- 0.926 (0.627-

0.988) 0.953) 0.973) 1.746) 1.224) 1.435)

NACEs†0.832 (0.613-

0.974)

0.807 (0.642-

0.987)

0.893 (0.579-

0.994)

0.882 (0.541-

1.483)

0.975 (0.568-

1.636)

0.932 (0.585-

1.582)

Values are shown as adjusted hazard ratios (95% confidence interval). CABG, coronary artery bypass graft; HF, heart failure; MACEs, major

adverse cardiac events; MI, myocardial infarction; NACEs, net adverse clinical events; Re-PCI, repeat percutaneous coronary intervention; ST,

stent thrombosis.

*MACEs included all-cause death, recurrent MI, or any revascularization with Re-PCI or CABG

†NACEs included all-cause death, recurrent MI, any revascularization with Re-PCI or CABG, stroke, HF readmission, or definite/probable ST.